{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma%2C&page=18", "query": { "condition": "Non-Hodgkin's Lymphoma,", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 2188, "total_pages": 219, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma%2C&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma%2C&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T13:01:46.248Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00384111", "title": "Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Follicular Lymphoma", "Lymphoma, Follicular" ], "interventions": [ { "name": "Zevalin Therapeutic Regimen", "type": "DRUG" }, { "name": "R-CVP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2006-10", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2022-01-14", "last_synced_at": "2026-10-15T13:01:46.248Z", "location_count": 6, "location_summary": "Jacksonville, Florida • St. Petersburg, Florida • Marietta, Georgia + 3 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Chattanooga", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00384111" }, { "nct_id": "NCT07648264", "title": "Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Secondary Immune Deficiency" ], "interventions": [ { "name": "IgPro20", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2026-09-15", "completion_date": "2029-09-27", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-15T13:01:46.248Z", "location_count": 17, "location_summary": "Orange, California • Denver, Colorado • Coral Springs, Florida + 14 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Lafayette", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07648264" }, { "nct_id": "NCT00840853", "title": "Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia (ALL)", "Chronic Lymphocytic Leukemia (CLL)", "Non Hodgkin's Lymphoma" ], "interventions": [ { "name": "CD19CAR/virus specific T cells", "type": "GENETIC" }, { "name": "Benadryl and Tylenol", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 68, "start_date": "2009-04", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-15T13:01:46.248Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00840853" }, { "nct_id": "NCT06018129", "title": "A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Classical Hodgkin Lymphoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "GEN3017", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 9, "start_date": "2023-09-21", "completion_date": "2025-02-05", "has_results": true, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-10-15T13:01:46.248Z", "location_count": 3, "location_summary": "Duarte, California • St Louis, Missouri • Houston, Texas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06018129" }, { "nct_id": "NCT00100477", "title": "Use of Topotecan in Patients With Refractory Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Leukemia" ], "interventions": [ { "name": "Topotecan", "type": "DRUG" }, { "name": "Mitozantrone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Department of Veterans Affairs", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 10, "start_date": "1998-08", "completion_date": "2001-06", "has_results": false, "last_update_posted_date": "2013-09-25", "last_synced_at": "2026-10-15T13:01:46.248Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100477" }, { "nct_id": "NCT06171945", "title": "Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer", "Physical Activity", "Cancer Survivorship", "Mental Health", "Obesity" ], "interventions": [ { "name": "AYA Connect intervention", "type": "BEHAVIORAL" }, { "name": "Positive Psychology (PP) intervention", "type": "BEHAVIORAL" }, { "name": "Positive Psychology Plus (PP+) intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 63, "start_date": "2024-03-01", "completion_date": "2025-10-05", "has_results": false, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-10-15T13:01:46.248Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06171945" }, { "nct_id": "NCT00184080", "title": "Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Elsamitrusin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2004-05", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2014-05-21", "last_synced_at": "2026-10-15T13:01:46.248Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00184080" }, { "nct_id": "NCT02919670", "title": "A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Myeloma", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Enterade", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" }, { "name": "Standard Supportive Care", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2016-10", "completion_date": "2020-07", "has_results": true, "last_update_posted_date": "2023-03-16", "last_synced_at": "2026-10-15T13:01:46.248Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02919670" }, { "nct_id": "NCT01447056", "title": "Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin Lymphoma", "Non-Hodgkin Lymphoma", "Lymphoproliferative Disorder", "Nasopharyngeal Carcinoma", "Leiomyosarcoma", "Severe Chronic Active EBV (SCAEBV)" ], "interventions": [ { "name": "LMP specific T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 37, "start_date": "2012-02", "completion_date": "2020-01-22", "has_results": false, "last_update_posted_date": "2020-02-07", "last_synced_at": "2026-10-15T13:01:46.248Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01447056" }, { "nct_id": "NCT03467373", "title": "A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Lymphoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Glofitamab", "type": "DRUG" }, { "name": "Obinutuzumab (G)", "type": "DRUG" }, { "name": "Rituximab (R)", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Polatuzumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2018-03-13", "completion_date": "2024-12-02", "has_results": false, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-10-15T13:01:46.248Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03467373" } ] }